2-溴-2-乙基丁酰胺 | 511-70-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 2-溴-2-乙基丁酰胺
• 英文名称: 2-bromo-2-ethylbutanamide
• 英文别名: diethylbromoacetamide；2-ethyl-2-bromo-butyric acid amide；2-Aethyl-2-brom-buttersaeure-amid；2-bromo-2-ethylbutyramide
• CAS: 511-70-6
• 化学式: C₆H₁₂BrNO
• 分子量: 194.071
• InChiKey: ACEYAMOAGUDVAQ-UHFFFAOYSA-N

物化性质

• 熔点：
  67°
• 沸点：
  261.6±23.0 °C(Predicted)
• 密度：
  1.3787 (rough estimate)
• 保留指数：
  1215;1215;1192;1205

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  9
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  43.1
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2924199090

反应信息

• 作为反应物：
  描述：

  2-溴-2-乙基丁酰胺 在 alcoholic alkali 作用下， 生成 3-戊酮
  参考文献：
  名称：

  Mossler, Monatshefte fur Chemie, 1908, vol. 29, p. 71

  摘要：

  DOI：
• 作为产物：
  描述：

  2-乙基丁腈 在 溴 作用下， 生成 2-溴-2-乙基丁酰胺
  参考文献：
  名称：

  DE186739

  摘要：

  公开号：

文献信息

• Nitric Oxide Releasing Prodrugs of Therapeutic Agents
  申请人：SATYAM Apparao

  公开号：US20110263526A1

  公开（公告）日：2011-10-27

  The present invention relates to nitric oxide releasing prodrugs of known drugs or therapeutic agents which are represented herein as compounds of formula (I) wherein the drugs or therapeutic agents contain one or more functional groups independently selected from a carboxylic acid, an amino, a hydroxyl and a sulfhydryl group. The invention also relates to processes for the preparation of the nitric oxide releasing prodrugs (the compounds of formula (I)), to pharmaceutical compositions containing them and to methods of using the prodrugs.

  本发明涉及已知药物或治疗剂的一氧化氮释放前药，其在此处表示为式(I)的化合物，其中药物或治疗剂包含一个或多个功能基团，独立地选自羧酸、氨基、羟基和巯基。该发明还涉及制备一氧化氮释放前药（式(I)的化合物）的方法，含有它们的药物组合物以及使用这些前药的方法。
• Synthesis of α-alkenyl-β-hydroxy adducts by α-addition of unprotected 4-bromocrotonic acid and amides with aldehydes and ketones by chromium(II)-mediated reactions
  作者：Ludger A. Wessjohann、Harry Wild、Leonildo A. Ferreira、Henri S. Schrekker

  DOI：10.1002/aoc.3488

  日期：2016.8

  The regioselective and diastereoselective chromium(II)‐mediated reactions of 4‐bromocrotonic acid or amides with aldehydes and ketones can proceed without the need to protect protic sites to generate the respective α‐alkenyl‐β‐hydroxy adducts, i.e. formally the addition of the α‐anion of a carboxylic acid or amide to an oxo‐compound is featured. Copyright © 2016 John Wiley & Sons, Ltd.

  可以进行4-溴巴豆酸或酰胺与醛和酮的区域选择性和非对映选择性铬（II）介导的反应，而无需保护质子位点以生成相应的α-烯基-β-羟基加合物，即正式添加具有羧酸或酰胺的α-阴离子与羰基化合物的特征。版权所有©2016 John Wiley＆Sons，Ltd.
• Technology for the Preparation of Microparticles
  申请人：Malakhov Michael

  公开号：US20090098207A1

  公开（公告）日：2009-04-16

  Microspheres are produced by contacting a solution of a macromolecule or small molecule in a solvent with an antisolvent and a counterion, and chilling the solution. The microspheres are useful for preparing pharmaceuticals, nutraceuticals, cosmetic products and the like of defined dimensions.

  微球是通过将溶液中的大分子或小分子与抗溶剂和对离子接触，并冷却溶液而制备的。这些微球可用于制备具有明确定义尺寸的药物、营养保健品、化妆品等产品。
• Mercapto-acylamino acid antihypertensives
  申请人：SCHERING CORPORATION

  公开号：EP0355784A1

  公开（公告）日：1990-02-28

  Mercapto-acylamino acids of the formula: wherein n is 0-4; R is R₁ is 1-3 substituents selected from the group consisting of hydrogen, halogeno, lower alkyl, cyclolower alkyl, lower alkoxy, hydroxy, aryl, aryloxy, cyano, aminomethyl, carboxy, lower alkoxy carbonyl and carbamyl; R₂ is hydrogen, R₁₁-- or R₁₁--OCH₂-, wherein R₁₁ is lower alkyl, aryl or arylmethyl; R³ is -OR₁₂, R₄, R₅, R₆, R₇, R₈, R₉ and R₁₀ are independently lower alkyl, aryl lower alkyl, (cyclolower alkyl) lower alkyl, substituted aryl lower alkyl or substituted (cyclolower alkyl) lower alkyl, wherein in the substituents on the aryl and cyclolower alkyl portions are 1-3 substituents selected from the group consisting of lower alkyl, hydroxy, halogeno, lower alkoxy and amino, or R₄ and R₅ are alkyl and together with the sulfur and carbon atoms to which they are attached form a 5-7 membered ring; R₁₂ and R₁₃ are independently hydrogen, lower alkyl or substituted lower alkyl wherein the substituents are selected from the group consisting of 1 or 2 hydroxy groups, 1 or 2 lower alkoxy groups, lower alkoxy lower alkoxy, halogeno, halogeno lower alkoxy, amino, mono- or di-lower alkylamino, aryl, substituted aryl wherein the substituents on aryl are 1-3 substituents selected from the group consisting of lower alkyl, hydroxy, halogeno, lower alkoxy and amino, and a 5-6 membered saturated ring comprising 1-2 oxygen atoms as ring members wherein the ring carbon atoms can be substituted with 0-2 lower alkyl substituents; or R₁₂ and R₁₃ together with the nitrogen to which they are attached complete a 5-7 membered ring, wherein one of the 4-6 ring members comprising R₁₂ and R₁₃ may be a nitrogen atom, an alkyl-substituted nitrogen atom or an oxygen atom, and wherein the ring may be substituted on the ring carbon atoms with substituents chosen from alkyl and hydroxy groups; R₁₄ is hydrogen, alkyl, carboxyalkyl, mercaptoalkyl, alkylthioalkyl, aminoalkyl, hydroxyalkyl, phenylalkyl, hydroxyphenylalkyl, guanidinoalkyl, imidazolylalkyl, indolylalkyl or carbamoylalkyl; the pharmaceutically acceptable salts thereof and their combinations with atrial natriuretic factors or angiotensin converting enzyme inhibitors are disclosed. Such preparations are useful for treating hypertension and congestive heart failure.

  公式为：其中n为0-4；R为R₁为从氢，卤代，低烷基，环低烷基，低烷氧基，羟基，芳基，芳基氧基，氰基，氨甲基，羧基，低烷氧羰基和氨基甲酰中选择的1-3个取代基；R₂为氢，R₁₁-或R₁₁-OCH₂-，其中R₁₁为低烷基，芳基或芳基甲基；R³为-OR₁₂，R₄、R₅、R₆、R₇、R₈、R₉和R₁₀分别为独立的低烷基，芳基低烷基，（环低烷基）低烷基，取代芳基低烷基或取代（环低烷基）低烷基，其中在芳基和环低烷基部分的取代基是从低烷基，羟基，卤代，低烷氧基和氨基中选择的1-3个取代基，或R₄和R₅为烷基，并与它们附着的硫和碳原子一起形成一个5-7成员环；R₁₂和R₁₃分别为氢，低烷基或取代低烷基，其中取代基是从1或2个羟基，1或2个低烷氧基，低烷氧基低烷氧基，卤代，卤代低烷氧基，氨基，单烷基或双烷基氨基，芳基，取代芳基中选择的取代基是从低烷基，羟基，卤代，低烷氧基和氨基中选择的1-3个取代基，以及包含1-2个氧原子作为环成员的5-6成员饱和环，其中环碳原子可以用0-2个低烷基取代基取代；或R₁₂和R₁₃与它们附着的氮一起形成一个5-7成员环，其中4-6个环成员之一包括R₁₂和R₁₃可以是氮原子，烷基取代的氮原子或氧原子，并且环上的环碳原子可以用从烷基和羟基中选择的取代基取代；R₁₄为氢，烷基，羧基烷基，巯基烷基，硫代烷基，氨基烷基，羟基烷基，苯基烷基，羟基苯基烷基，鸟氨酸基烷基，咪唑基烷基，吲哚基烷基或氨甲酰基烷基；公开了其药学上可接受的盐及其与心房利钠肽因子或血管紧张素转化酶抑制剂的组合。这样的制剂对治疗高血压和充血性心力衰竭有用。
• Compositions and methods to effect the release profile in the transdermal administration of active agents
  申请人：——

  公开号：US20020004065A1

  公开（公告）日：2002-01-10

  Compositions and methods for the transdermal delivery of active agents up to a period of seven days or more at substantially a zero-order release rate comprising a pharmaceutically acceptable adhesive matrix and a polymeric plastic material that provides a release rate regulating effect on the active agents.

  本发明涉及一种用于经皮递送活性药剂的组合物和方法，该组合物和方法能够在持续时间为七天或更长时间内以几乎零阶释放速率递送活性药剂，包括一种药学上可接受的粘合基质和一种聚合物塑料材料，该聚合物塑料材料对活性药剂具有释放速率调节作用。

表征谱图